World Generic Markets Issue - IGBA Special 301 Submission Highlights Need For Common Ground - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "World Generic Markets Issue 281 (V15 I14)" report to their offering.

From a pharmaceutical perspective, the USTR's Special 301 Report has generally been seen as an opportunity to criticise countries' intellectual property regimes in an effort to bolster patent monopolies and protect branded drug revenues. However, the IGBA's submission to the USTR shows that the report can also be an opportunity to highlight potential deficiencies that hinder generic drug access. Well-functioning intellectual property is in the interests of both the branded and generic industries; finding common ground will protect revenues and strengthen access.

Key Topics Covered:

  1. IGBA Special 301 Submission Highlights Need For Common Ground
  2. Sandoz Canada Launches Tobramycin Authorised Generic
  3. Biocon Enters Insulin Agreement With Lab PiSA
  4. Prize Fund Concept Rethinks Innovation/Reward Model
  5. Allergan Confirms Paclitaxel Patent Challenge
  6. Breckenridge Gains Gabapentin Approval
  7. Orchid Gains Rasagiline Approval
  8. Glenmark Gains Frovatriptan Approval And Lacosamide Tentative Approval
  9. Aurobindo's Ibandronate Approved
  10. Teligent Launches Cefotetan
  11. Teva Launches Acamprosate In US
  12. Lupin Completes Gavis And Novel Acquisitions
  13. Apotex Launches Mometasone Nasal Spray
  14. Perrigo And Allergan Launch OTC Guaifenesin
  15. Lialda Weathers Generic Storms But Remains At Threat From PTO Ruling
  16. Rising Launches Lithium Carbonate And Metronidazole Tablets
  17. Ajanta Launches Levetiracetam In US
  18. Aurobindo Gains New US Drug Approvals
  19. Amneal Launches Diclofenac Sodium Gel
  20. Hikma, Lannett Gain Temolozomide Approvals
  21. Lannett Gains Potassium Chloride Approval
  22. Mylan Launches Tramadol ER Tablets
  23. Lupin Launches Donepezil Tablets
  24. ANI Receives Oxycodone Approval
  25. ANI Closes Inderal LA Acquisition
  26. Inter Partes Review Case Will Hold Timely Generic Access In The Balance
  27. Perrigo Seeks To Improve Branded Consumer Healthcare Business
  28. Actavis Launches Gliclazide In UK
  29. GSK's Access Proposal Is Bold But Implementation Will Be Key
  30. Teva Takeda Yakuhin Established
  31. Africa/Middle East
  32. Hikma Looking To US To Boost Sales

For more information visit http://www.researchandmarkets.com/research/lvkd4p/world_generic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Generic Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Generic Drugs